Roche and Take­da try on Em­u­late’s 'or­gan chip' tech for R&D

Two phar­ma gi­ants — Roche and Take­da — are buy­ing in­to a drug test­ing tech­nol­o­gy that wants to be the next gen­er­a­tion’s “lab rat,” ink­ing part­ner­ships with the tech’s mak­er to in­tro­duce the sys­tems to their R&D labs.

The tech, made by Wyss In­sti­tute spin­off Em­u­late, in­cludes small chips de­signed to hold liv­ing cells in cham­bers. These chips are en­gi­neered to recre­ate the en­vi­ron­ment cells might ex­pe­ri­ence in the hu­man body, in­tro­duc­ing me­chan­i­cal forces that mim­ic breath­ing, for ex­am­ple.

Geral­dine Hamil­ton

Test­ing drugs in cells that are in dish­es — or even test­ing drugs in an­i­mals — is a flawed process, Em­u­late’s pres­i­dent and CSO Geral­dine Hamil­ton tells me. An­i­mals are not hu­mans, and so they of­ten fail to pre­dict how drugs will per­form in pa­tients. And cells in dish­es don’t work like they do in the hu­man body, so they aren’t very pre­dic­tive ei­ther.

Com­pa­nies have been work­ing on bet­ter ways to test drugs for a while, with com­pa­nies like San Diego-based Organo­vo “bio­print­ing” hu­man tis­sue and Ste­moniX build­ing “mi­cro or­gans” by struc­tur­ing hu­man iP­SC-de­rived cells in­to mi­cro­tis­sues.

But Hamil­ton says both these tech­nolo­gies are lack­ing.

“There are key fac­tors miss­ing: me­chan­i­cal forces, dy­nam­ic flow sys­tems, cir­cu­lat­ing im­mune cells,” she says. “While they re­tain some nice bi­olo­gies, they’re miss­ing these el­e­ments.”

Em­u­late’s S-1 Or­gan-Chip tech­nol­o­gy. Pho­to cour­tesy of Em­u­late.

Now Roche and Take­da are pay­ing to take Em­u­late’s tech for a test dri­ve. Roche will use Em­u­late’s Hu­man Em­u­la­tion Sys­tem across mul­ti­ple R&D pro­grams in a three-year part­ner­ship, with the aim of dis­cov­er­ing and de­vel­op­ing new class­es of ther­a­peu­tic an­ti­bod­ies and drug com­bi­na­tions. One goal of the part­ner­ship is to use pa­tient-de­rived cells to make head­way on the idea of per­son­al­ized drug safe­ty, us­ing the chips to test how a pa­tient or pa­tient group might re­spond to a drug. Sci­en­tists from both com­pa­nies will work with­in Em­u­late’s labs in Boston. The re­search will ini­tial­ly fo­cus on us­ing Em­u­late’s “Lung-Chip” and “Brain-Chip,” with the op­por­tu­ni­ty to ex­pand to use oth­er “Or­gan-Chips.”

Take­da is specif­i­cal­ly us­ing Em­u­late’s “In­stes­tine-Chip” for gas­troin­testi­nal dis­ease R&D.

“The abil­i­ty to ac­cu­rate­ly mod­el the in­testi­nal ep­ithe­li­um is a key to open­ing up new in­sights in­to the com­plex path­ways of GI dis­eases and drug mech­a­nisms of ac­tion, and we are de­light­ed to ap­ply our In­tes­tine-Chip to sup­port drug in­no­va­tion with Take­da, a world leader in de­vel­op­ing treat­ments for GI dis­eases,” Hamil­ton said.

Fi­nan­cial de­tails of the part­ner­ships were not dis­closed.


Vil­li-like struc­tures in­side Em­u­late’s In­tes­tine-Chip, which will be used by Take­da in new part­ner­ship. Em­u­late

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Overview
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

Paul Hudson. Sanofi

New Sanofi CEO Hud­son adds next-gen can­cer drug tech to the R&D quest, buy­ing Syn­thorx for $2.5B

When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about.

The French pharma giant announced early Monday that it is snagging San Diego biotech Synthorx in a $2.5 billion deal. That marks an affordable bolt-on for Sanofi but a considerable return for Synthorx backers, including Avalon, RA Capital and OrbiMed: At $68 per share, the price represents a 172% premium to Friday’s closing.

Synthorx’s take on alternative IL-2 drugs for both cancer and autoimmune disorders — enabled by a synthetic DNA base pair pioneered by Scripps professor Floyd Romesberg — “fits perfectly” with the kind of innovation that he wants at Sanofi, Hudson said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,100+ biopharma pros reading Endpoints daily — and it's free.

KalVis­ta's di­a­bet­ic mac­u­lar ede­ma da­ta falls short — will Mer­ck walk away?

Merck’s 2017 bet on KalVista Pharmaceuticals may have soured, after the UK/US-based biotech’s lead drug failed a mid-stage study in patients with diabetic macular edema (DME).

Two doses of the intravitreal injection, KVD001, were tested against a placebo in a 129-patient trial. Enrolled patients continued to experience significant inflammation and diminished visual acuity, despite anti-VEGF therapy. Patients with DME — the most frequent cause of vision loss related to diabetes — are typically treated with anti-VEGF therapies such as Regeneron’s flagship Eylea or Roche’s Avastin and Lucentis.

Roger Perlmutter, Merck

#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

Just a few months after making a splash at the European Hematology Association scientific confab with an early snapshot of positive data for their BTK inhibitor ARQ 531, ArQule has won a $2.7 billion buyout deal from Merck.

Merck is scooping up a next-gen BTK drug — which is making a splash at ASH today — from ArQule in an M&A pact set at $20 a share $ARQL. That’s more than twice Friday’s $9.66 close. And Merck R&D chief Roger Perlmutter heralded a deal that nets “multiple clinical-stage oral kinase inhibitors.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,100+ biopharma pros reading Endpoints daily — and it's free.

Ob­sE­va makes case for best-in-class hor­mone sup­pres­sive ther­a­py in pos­i­tive uter­ine fi­broid study

About a month after the Swiss biotech disclosed a failed late-stage study in its IVF program, ObsEva on Monday unveiled positive pivotal data on its experimental treatment for heavy menstrual bleeding triggered by uterine fibroids.

ObsEva in-licensed the drug, linzagolix, from Japan’s Kissei Pharmaceutical in 2015. Two doses of the drug (100 mg and 200 mg) were tested against a placebo in the 535-patient Phase III study, dubbed PRIMROSE 2, in patients who were both on and off hormonal add-back therapy (ABT).

Samit Hirawat. Bristol-Myers Squibb

Bris­tol-My­ers is mak­ing a bee-line to the FDA with pos­i­tive liso-cel da­ta — but is it too late in the CAR-T game?

Bristol-Myers Squibb came to ASH this past weekend with a variety of messages on the new cancer drugs they had acquired in the big Celgene buyout, including liso-cel, the lead CAR-T program picked up in the $9 billion Juno acquisition. And one of the most important was that they had the pivotal efficacy and safety data needed to snag an approval from the FDA next year, with the BLA on track for a filing this month.

J&J team shows off 'break­through' BC­MA CAR-T da­ta, and that could cause a big headache at blue­bird and Bris­tol-My­ers

Just hours after J&J’s oncology team bragged about scoring a breakthrough therapy designation for their BCMA CAR-T drug, they pulled the wraps off of the multiple myeloma data for JNJ-4528 that impressed the FDA. And it’s easy to see why they may well be on a short path to a landmark approval — which may well be making the rival team at bluebird/Bristol-Myers more than a little nervous.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,100+ biopharma pros reading Endpoints daily — and it's free.

J&J's Mathai Mammen at an Endpoints News event in Boston, June 2018 (Photo: Rob Tannenbaum for Endpoints News)

J&J fronts $750M cash to grab a failed can­cer drug that’s been re­pur­posed as a pow­er­ful an­ti-in­flam­ma­to­ry

J&J has stepped up with one of its blockbuster drug buys, agreeing to pay Austin-based XBiotech $XBIT $750 million in cash and up to $600 million more in milestones for their late stage-ready anti-inflammatory drug bermekimab — which some longtime biotech observers may recognize as a failed cancer therapy with a disaster-prone past.

The drug targets the IL-1a pathway. J&J $JNJ R&D chief Mathai Mammen is cutting a check for a drug that has produced positive mid-stage data in patients suffering from a skin condition called hidradenitis suppurativa with another mid-stage program underway for atopic dermatitis.

That puts J&J in charge of a drug on the threshold of pivotal — though pricey — R&D work for a broad patient group with other related fields to explore. And it’s a very busy development arena.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,100+ biopharma pros reading Endpoints daily — and it's free.

Jake Van Naarden, Josh Bilenker, Nisha Nanda (Credit: Loxo, Aisling Capital)

Josh Bilenker and his Loxo crew are tak­ing the reins on on­col­o­gy R&D at Eli Lil­ly, culling the weak and map­ping a new path

Josh Bilenker, Jake Van Naarden and Nisha Nanda came out of Eli Lilly’s $8 billion Loxo Oncology buyout with a bundle of cash and plenty of choices on what they could do next. Start a new company, go public. Live on the beach in 5-star luxury. Contemplate the stars — in their own observatory.

So what are they doing?

They formed a new executive team that is taking over the management of Eli Lilly’s hundreds-strong oncology R&D group — essentially using Loxo as a base for a bold new experiment in Big Pharma R&D in an attempt to create a true biotech environment with the deep pockets of a top-15 industry player. They’ve recruited David Hyman from Memorial Sloan Kettering to join the team as chief medical officer. And the mandate includes culling out the oncology pipeline, highlighting their star prospects and going after new programs wherever they can find the best prospects.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,100+ biopharma pros reading Endpoints daily — and it's free.